Author's response to reviews

Title: MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1

Authors:

Jing Liu Dr (asfollowing@163.com)
Zhi-Li Liu Dr (wzx_nanjing@yahoo.com.cn)
Ming Sun Dr (ruiwangrui@yahoo.com.cn)
Wei De Prof (dewei_nanjing@yahoo.com.cn)
Zhao-Xia Wang Prof (wangzhaox@yahoo.com.cn)

Version: 2 Date: 6 July 2012

Author's response to reviews: see over
6st July, 2012

Dear Editors:

Previously, we have published a manuscript about clinical significance of polo-like kinase 1 expression in NSCLC [Wang ZX, Xue D, Liu ZL, Lu BB, Bian HB, Pan X, Yin YM. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. Int J Biochem Cell Biol. 2012 Jan;44(1):200-10]. However, the mechanisms of PLK1 overexpression are still unclear. On behalf of my co-authors, I am submitting the enclosed material “MiR-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting PLK1” for possible publication in your journal.

The manuscript must have been performed with the approval of an appropriate ethics committee and research carried out on humans must be in compliance with the Helsinki Declaration. A statement to this effect has appeared in the Methods section of the manuscript. We certify that we have participated sufficiently in the work to take public responsibility for the appropriateness of the experimental design and method, and the collection, analysis, and interpretation of the data.

We have reviewed the final version of the manuscript and approve it for publication. To the best of our knowledge and belief, this manuscript has not been published in whole or in part nor is it being considered for publication elsewhere.

Best Regards.

Yours Sincerely,

Zhao-Xia Wang

Co-authors’ signatures:

Jing Liu†, Zhi-Li Liu†, Ming Sun‡, Wei De‡, Zhao-Xia Wang †∗

∗Correspondence: wangzhaox@yahoo.com.cn.

†Contributed equally.

‡Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, 121 Jiangjiayuan Road, Nanjing 210011, Jiangsu, P.R. China.